| Patient | Ann Richards |
|---|---|
| Date of birth | 1962-09-01 |
| Identifiers | MRN HR-ML019-SYN; SSN (made up) 000-19-3381 |
| Document date | 2026-02-10 |
| Author | Rosalind Teague, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
The patient attends this visit for new patient visit for bone health after a fall with a hand fracture. [S]
Lumbar spine (L1-L4) T-score: -2.3 (low); Femoral neck T-score: -2 (low); Total hip T-score: -1.7 (low); FRAX 10-year major osteoporotic fracture risk: 22%; FRAX 10-year hip fracture risk: 3.6%; Calcium: 9.4 mg/dL; Albumin: 4.2 g/dL; Creatinine: 0.8 mg/dL; eGFR: 81 mL/min/1.73 m²; Phosphate: 3.5 mg/dL; Magnesium: 2 mg/dL; Alkaline phosphatase: 84 U/L; PTH: 54 pg/mL; TSH: 1.9 mIU/L; Hemoglobin: 13.3 g/dL; ALT: 21 U/L; 25-hydroxyvitamin D: 24 ng/mL (low); Serum CTX (fasting morning sample): 560 pg/mL; PHQ-9: 2; AUDIT-C: 0. [S]
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-02-10 | Body height | 164 | cm | S |
| 2026-02-10 | Body weight | 66 | kg | S |
| 2026-02-10 | Body mass index (BMI) [Ratio] | 24.5 | kg/m2 | S |
| 2026-02-10 | Systolic blood pressure | 124 | mm[Hg] | S |
| 2026-02-10 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-02-10 | Heart rate | 72 | /min | S |
| 2026-02-10 | Respiratory rate | 14 | /min | S |
| 2026-02-10 | Body temperature | 36.6 | Cel | S |
| 2026-02-10 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-02-10 | DXA Lumbar spine [T-score] Bone density | -2.3 | {T-score} | -1.0 or higher is normal; between -1.0 and -2.5 is low bone mass (osteopenia); -2.5 or lower is osteoporosis | Low | S |
| 2026-02-10 | DXA Femur [T-score] Bone density | -2 | {T-score} | -1.0 or higher is normal; between -1.0 and -2.5 is low bone mass (osteopenia); -2.5 or lower is osteoporosis | Low | S |
| 2026-02-10 | DXA Hip [T-score] Bone density | -1.7 | {T-score} | -1.0 or higher is normal; between -1.0 and -2.5 is low bone mass (osteopenia); -2.5 or lower is osteoporosis | Low | S |
| 2026-02-10 | Major osteoporotic fracture 10-year probability [Likelihood] Fracture Risk Assessment | 22 | % | S | ||
| 2026-02-10 | Hip fracture 10-year probability [Likelihood] Fracture Risk Assessment | 3.6 | % | S | ||
| 2026-02-10 | Calcium [Mass/volume] in Serum or Plasma | 9.4 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-02-10 | Albumin [Mass/volume] in Serum or Plasma | 4.2 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-02-10 | Creatinine [Mass/volume] in Serum or Plasma | 0.8 | mg/dL | 0.5-1 mg/dL | Normal | S |
| 2026-02-10 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 81 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-02-10 | Phosphate [Mass/volume] in Serum or Plasma | 3.5 | mg/dL | 2.5-4.5 mg/dL | Normal | S |
| 2026-02-10 | Magnesium [Mass/volume] in Serum or Plasma | 2 | mg/dL | 1.7-2.4 mg/dL | Normal | S |
| 2026-02-10 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 84 | U/L | 40-120 U/L | Normal | S |
| 2026-02-10 | Parathyrin.intact [Mass/volume] in Serum or Plasma | 54 | pg/mL | 15-65 pg/mL | Normal | S |
| 2026-02-10 | Thyrotropin [Units/volume] in Serum or Plasma | 1.9 | m[IU]/L | 0.4-4 mIU/L | Normal | S |
| 2026-02-10 | Hemoglobin [Mass/volume] in Blood | 13.3 | g/dL | 12-15.5 g/dL | Normal | S |
| 2026-02-10 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 21 | U/L | 7-35 U/L | Normal | S |
| 2026-02-10 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 24 | ng/mL | Target 30 ng/mL or higher before and during osteoporosis treatment | Low | S |
| 2026-02-10 | Collagen crosslinked C-telopeptide [Mass/volume] in Serum or Plasma | 560 | pg/mL | Postmenopausal reference interval 104 to 1008 pg/mL; a fall of more than about 30 percent on antiresorptive therapy indicates response | Normal | S |
| 2026-02-10 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 2 | {score} | S | ||
| 2026-02-10 | Total score [AUDIT-C] | 0 | {score} | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Cholecalciferol (vitamin D3) 50 mcg (2000 units) oral tablet, one tablet daily | One tablet by mouth daily | Oral route | 2026-02-10 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Low bone mass (osteopenia) of the lumbar spine and hip on DXA, lowest T-score -2.3 at the lumbar spine (femoral neck -2.0, total hip -1.7), with a 10-year FRAX risk above the treatment thresholds (major osteoporotic fracture 22 percent, hip 3.6 percent); not osteoporosis by T-score, but meets the AACE 2020 clinical criteria for osteoporosis (low bone mass with a FRAX risk above threshold) | active | confirmed | M85.89 | S — Synthetic modern DXA and FRAX classification linked to her publicly described osteopenia (early osteoporosis) after a fall with a hand fracture. |
| Alcohol use disorder in sustained remission for more than fifteen years, since treatment; no alcohol since | active | confirmed | F10.21 | S — Synthetic modern coding of her publicly described heavy drinking and long recovery; listed because remission protects bone and lowers fall risk, and it is reviewed at each visit. |
| History of falls: a fall from standing height with a hand fracture last year (and, in one account, a second fall with an ankle fracture); no falls since | active | confirmed | Z91.81 | S — Synthetic modern entry linked to her publicly described falls and fractures. |